XML 20 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended March 31,
 20252024
Net product revenue$11,601.2 $7,796.5 
Collaboration and other revenue
1,127.3 971.5 
Revenue$12,728.5 $8,768.0 
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront, and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue resulting from our collaboration with Boehringer Ingelheim discussed in Note 4, as well as the sale of product rights. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Adjustments to Revenue
Adjustments to revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 1 percent and approximately 3 percent of U.S. revenue during the three months ended March 31, 2025 and 2024, respectively.
Disaggregation of Revenue
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product:
Three Months Ended March 31,
 20252024
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Cardiometabolic Health:
Mounjaro$2,655.9 $1,185.9 $3,841.8 $1,520.4 $286.2 $1,806.5 
Zepbound2,305.4 6.5 2,311.9 517.4 — 517.4 
Trulicity770.5 324.7 1,095.2 1,081.9 374.4 1,456.3 
Jardiance(1)
309.8 704.6 1,014.4 368.2 318.3 686.5 
Other cardiometabolic health535.1 409.7 944.8 602.1 424.1 1,026.3 
Total cardiometabolic health6,576.7 2,631.4 9,208.1 4,090.0 1,403.0 5,493.0 
Oncology:
Verzenio657.6 501.3 1,158.9 638.2 412.1 1,050.3 
Other oncology388.2 400.4 788.6 360.1 399.6 759.7 
Total oncology1,045.8 901.7 1,947.5 998.3 811.7 1,810.0 
Immunology:
Taltz476.5 285.4 761.9 347.1 257.0 604.1 
Other immunology101.6 224.6 326.1 50.1 179.8 229.9 
Total immunology578.1 510.0 1,088.0 397.2 436.8 834.0 
Neuroscience189.3 82.8 272.1 163.2 225.9 389.1 
Other99.5 113.3 212.9 45.7 196.2 241.9 
Revenue$8,489.4 $4,239.1 $12,728.5 $5,694.4 $3,073.7 $8,768.0 
(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.

The following table summarizes revenue by geographical area:
Three Months Ended March 31,
20252024
Revenue(1):
U.S.$8,489.4 $5,694.4 
Europe2,388.7 1,440.7 
China450.8 376.2 
Japan402.2 363.9 
Rest of world997.4 892.9 
Revenue$12,728.5 $8,768.0 
(1) Revenue is attributed to the countries based on the location of the customer or other party.